Germany headquartered Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has signed an agreement to acquire Polyplus for approximately 2.4 billion euros from private investors, including ARCHIMED and WP GG Holdings IV B.V., an affiliate of Warburg Pincus.

Polyplus, with around 270 employees, develops and produces transfection as well as other DNA/RNA delivery reagents and plasmid DNA in high quality and GMP grade. These are key components in the production of viral vectors used in cell and gene therapies and other advanced medicinal therapeutic products.

Recording significant growth rates, Polyplus is expected to generate sales revenue in the upper double-digit million-euro range and a very substantial EBITDA margin in 2023. The proposed transaction is subject to customary conditions, including completion of the information and consultation of the works’ council and approval by regulatory authorities and is expected to close during the third quarter of 2023.

Founded in 2001, Polyplus is based in Strasbourg, France, and has locations in France, Belgium, the US, and China. The company has been expanding its focus beyond transfection reagents through acquisitions in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening its upstream portfolio for gene therapies as well as gene-modified cell therapies.